EXACENT To Provide IT VIirtualization To HybridChart

EXACENT To Provide IT VIirtualization To HybridChart

Newly Founded Medical IT Company Launches into EXACENT's Virtualized Environment

Scottsdale, Arizona (PRWEB) February 19, 2009 -- EXACENT, the leading enterprise grade - on demand virtual data center (http://www.exacent.com/), is pleased to announce HybridChart as a new express virtual server customer.

HybridChart, a Scottsdale based company, has developed innovative and user-friendly products for medical practices of all specilities. An alternative to EMR, HybridChart manages hospital rounding, medical transcription and office communication without the need for large capital investment or the disruption to individual practice styles.

Every customized version of HybridChart has the ability to improve efficiency of daily operations and reduce practice overhead. Selective digitization of medical information provides the benefits of instant access to information, without taking on any of the downsides of complete electronic conversion. Wherever there is an internet connection, secure and HIPAA-compliant access to all crucial patient data is available.

HybridChart utilizes EXACENT as their turnkey virtual data center (http://www.exacent.com/) solution where all their information will be stored and available for access 24/7/365 via the Internet. EXACENT's services will allow HybridChart to increase their performance, reliability, security, scalability, as well as support leveraging best of class infrastructure and virtualization. This combination of technology allows HybridChart to "go green" by utilizing less hardware and less space for their virtual data center (http://www.exacent.com/) needs. In addition, as HybridChart continues to expand they have the ability to dynamically and effortlessly grow their infrastructure to match their customers' needs.

"By utilizing EXACENT virtualization, HybridChart will now have the same access to the data center performance, reliability, security, scalability and support as a Fortune 100 company," said David Shepard, General Manager of EXACENT. "I am pleased to be working with such a great technology forward company."

"EXACENT provides the security and reliability we need with regards to sensitive patient information," said Dr. Gregory Sanders, HybridChart CEO. "The degree of service and support we have received is unprecedented in this industry."

EXACENT will provide HybridChart with always on, secure, data grade power and network which is guaranteed with a 100 percent uptime Service Level Agreement. EXACENT resides in i/o Data Centers Phoenix Colocation (http://www.iodatacenters.com/data-centers/arizona/phoenix-data-center.aspx) Facility, a physically secure, SAS 70 Type II certified data center. EXACENT also adheres to PCI DSS (Payment Card Industry Data Security Standard) best practices to secure web property, intellectual property and payment account data for its clients.     

About EXACENT

Scottsdale-based EXACENT is the premier global provider of on-demand enterprise grade infrastructure that is secure, scalable, efficient, redundant and highly available. Its offerings allow organizations to eliminate capital expenditures, infrastructure management and provide companies with the best infrastructure available. EXACENT is located in i/o Data Centers (http://www.iodatacenters.com), an industry leader in delivering the highest quality, fully scalable and completely reliable data center and Phoenix colocation (http://www.iodatacenters.com/data-centers/arizona/phoenix-data-center.aspx) solutions with 100 percent uptime. For more information, go to www.exacent.com.

About HybridChart

HybridChart software was developed by Gregory P. Sanders, MD, FACC - a practicing, Harvard-trained, Board-certified cardiologist. Dr. Sanders began his career in software development long before entering medical training. After years of clinical practice and frustration with corporate solutions to the electronic needs of the medical community, Dr. Sanders set out to provide a more realistic and relevant electronic environment. HybridChart has partnered with MedSoft, a full-service company, providing product implementation, training and customer service. HybridChart, commercially ready since November 2008, is available to practices of any specialty or setting. For more information, go to www.HybridChart.com.

###

Contact Information Sarah Slade

Exacent

http://www.exacent.com

866.282.5451

Gregory Sanders MD

HybridChart

http://www.hybridchart.com

480.329.0914

Toxic Element Research Foundation Announces Its Latest Worldwide Educational Programs for Health Professionals and Patients

Toxic Element Research Foundation Announces Its Latest Worldwide Educational Programs for Health Professionals and Patients

Toxic Elements Research Foundation (TERF), a non profit research foundation, announces its series of dental related health care reports under the title of 'Elements of Disease.'

Colorado Springs, CO (PRWEB) February 19, 2009 -- Toxic Elements Research Foundation (TERF), a non profit research foundation, announces its series of dental related health care reports under the title of 'Elements of Disease.' Toxicity, or the inadvertent poisoning of our population, is the focal point of the Toxic Element Research Foundation. For the past thirty years, TERF has funded a wide variety of research to discover the connection between dental materials and health. Its primary focus was its research on Mercury containing dental amalgam (silver) fillings and the dangers associated with it. The FDA has finally admitted many of these dangers. TERF has turned its attention to other dental materials and procedures, and is now releasing the results of this highly controversial research to the news media and general public.

This first series of reports identifies various factions of blood tests that demonstrate extremely unhealthy aspects of not only common silver mercury fillings, but introduces the role of bacterial toxins from root canals, dental implants and cavitations. A surprising expose is presented on 'cavitations', or defects in the bone where wisdom teeth were removed. Through the use of sophisticated DNA technology, identification of the especially damaging anaerobic bacteria (those who live in the absence of oxygen) that are found in root canals and cavitations has shed new light on the potential cause and advanced treatment for diseases thought to be incurable. This research confirms data discovered and presented to the American Dental Association over ninety years ago.

Examples of the diseases that have been associated with the bacterium discovered hidden within dental procedures are MS, ALS, AD, leukemia and diabetes. With proper dental treatment and recognition of these sources of toxins and their eradication, many patients can be improved, and TERF believes most could have been avoided entirely. New generations will not have these new diseases to be concerned about IF research institutions can be encouraged to explore these newly discovered avenues of their cause.

Results and correlations are provided free of charge in order to stimulate investigative type of reporters to assist the Toxic Element Research Foundation in generating awareness in the public. TERF has created a media outreach program where media writers can visit the web site - www.terftalks.com - and e-mail their choice of two topics in addition to the basic report up on root canals, the incubators. Other topics include: cavitations, the caverns of deceit; dental implants, the invitation for Alzheimer's; cholesterol, the giver of life; chronic fatigue, complexity encompassed; sodium and potassium, the butlers; albumin, the primary detoxifier; porphyrins, the origin of all energy; methyl mercury on the red cell, the biomarker of recovery; and white blood cells, our primary defense against autoimmune diseases.

About Toxic Elements Research Foundation

TERF, a non-profit research foundation, is dedicated to stimulating interest in the research community as well as informing the public to become aware of potential problems associated with dental materials and procedures. Informed consent of potential problems makes for better informed decisions by the patient - especially where health is at risk.

###

Contact Information Jamie Tolle

Toxic Element Research Foundation

http://www.terftalks.com

719-262-2978

Landmark Trial Provides Vital Information for Cardiac Disease Treatment

Landmark Trial Provides Vital Information for Cardiac Disease Treatment

NorthShore University HealthSystem Ted Feldman, M.D., Lead Investigator

Evanston, IL. -- NorthShore University HealthSystem (http://www.northshore.org/) (NorthShore) has played a leading role in a landmark clinical trial comparing two forms of treatment for patients with severe coronary artery disease (CAD). The results were published on-line in this week's issue of the New England Journal of Medicine.

The SYNTAX trial was a clinical research study that compared percutaneous coronary intervention (PCI) with drug-eluting stents and coronary artery bypass surgery (CABG) in patients with three-vessel and left main coronary disease. The trial results did not show any statistically significant differences between PCI and CABG in rates of death or heart attack, an excess of stroke in the CABG treated patients, and a greater need for repeat PCI procedures in the stent treated patients. These are better outcomes for PCI than have been seen in prior trials in less complex patients.

"At NorthShore, we experienced stunning outcomes in patients whose only option would have previously been bypass surgery," said Ted Feldman, M.D, F.S.C.A.I., Director of Cardiac Catheterization Laboratory, NorthShore University HealthSystem, and a lead investigator of the trial. "The data in this study will provide cardiologists with additional information as they determine treatment therapy for patients with complex CAD."

The trial is the first randomized, controlled clinical trial to compare these two treatments in patients with left main disease and/or three-vessel disease, who are typically treated with CABG and represent a population with far more complex anatomy and advanced disease than those studied in prior drug-eluting stent (DES) clinical trials.

There were 1,800 patients enrolled in the randomized arm of the trial. All patients were assessed by a multidisciplinary team including an interventional cardiologist and a cardiac surgeon. If both the cardiologist and surgeon felt that they could offer equivalent complete revascularization, patients were randomized 1:1 into one of the two treatment strategies. If either the cardiologist or surgeon felt that one or the other revascularization technique was the preferred option, due to technical considerations or co-morbidity, for example, then patients were recruited into one of two parallel, nested registries for PCI or CABG. Thus, patients in the PCI registry had been rejected for cardiac surgery.

About NorthShore University HealthSystem

Headquartered in Evanston, Ill., NorthShore University HealthSystem (NorthShore) is a comprehensive, fully integrated, healthcare delivery system that serves the greater North Shore and northern Illinois communities. The system includes three Hospitals--Evanston Hospital, Glenbrook Hospital and Highland Park Hospital--and a fourth, Skokie-based Rush North Shore Hospital, to be added in January 2009. In addition, the healthsystem has more than 2,000 affiliated physicians, including a 550-physician, multispecialty physician group practice with over 70 office locations-- NorthShore University HealthSystem Medical Group. Further, NorthShore is committed to excellence in its academic mission and supports teaching and research as the principal teaching affiliate of the University of Chicago's Pritzker School of Medicine. The NorthShore University HealthSystem Research Institute, with more than $100 million of grants, focuses on clinical and translational research, including leadership in outcomes research and clinical trials.

NorthShore has annual revenues of $1.5 billion and a staff of more than 8,000. The healthsystem has significant capabilities in a wide spectrum of clinical programs, including cancer, heart, orthopaedics, high-risk maternity and pediatrics. NorthShore is a national leader in the implementation of innovative technologies, including electronic medical records, (EMR ). In 2003, the healthsystem was among the first in the country to successfully launch a systemwide EMR with demonstrable benefits in quality, safety, efficiency and service to patients. NorthShore has been recognized by multiple national organizations for this notable achievement. Visit http://www.northshore.org/

CONTACT: Amy Ferguson

Senior Director, Public Relations

NorthShore University HealthSystem

(847) 570-3146

###

Contact Information Amy Ferguson

Northshore University HealthSystem

http://www.northshore.org/

847-570-3146

Dr. Larry Kaskel, Medical Director of the Heart Attack Prevention Center, to Speak March 4th at CardioCareLive about FirstLine Therapy

Dr. Larry Kaskel, Medical Director of the Heart Attack Prevention Center, to Speak March 4th at CardioCareLive about FirstLine Therapy

CardioCareLive, a medical conference that takes place entirely online, announces participation of Dr. Larry Kaskel, Founder and Medical Director of the Heart Attack Prevention Center. Dr. Kaskel to present "Improved Patient Outcomes and Enhanced Revenue with Therapeutic Lifestyle Changes."

Needham, MA (PRWEB) February 18, 2009 -- CardioCareLive (http://www.cardiocarelive.com), the first of its kind online medical conference for primary care physicians and other healthcare professionals who work with patients with cardiometabolic risk factors, today announced Metagenics as an exhibitor at the March 3-4 event. Metagenics will also sponsor a session by Dr. Larry Kaskel, Founder and Medical Director of the Heart Attack Prevention Center, who will speak on "Improved Patient Outcomes and Enhanced Revenue with Therapeutic Lifestyle Changes." Attendees can watch this live video session and have their questions addressed in near real-time by Dr. Kaskel.

CardioCareLive provides an opportunity for healthcare practitioners to learn and interact with leading practitioners and stay informed about new treatments and therapies for patients with cardiovascular risk factors, such as Metagenics' FirstLine Therapy® program. This turn-key therapeutic lifestyle change program is easy to integrate into a practice and enables primary care physicians to provide lifestyle change therapies in a systematic way that is successful for the patient while also a revenue driver for the practice.

"Physicians recognize the need to guide their patients through lifestyle changes in order to achieve better outcomes," said Mike Katke, VP of Medical Marketing for Metagenics. "But time constraints and practice processes make ongoing care of this type challenging. FirstLine Therapy provides a systematic approach to aid patients in implementing lifestyle changes that can be truly successful."

CardioCareLive recognizes the need for time-constrained physicians to stay current with the latest healthcare innovations. The event delivers all the benefits of a physical medical conference, with live keynote presentations, lectures, peer networking and an exhibit floor, from the convenience of a computer. To view a complete list of speakers, agenda, or to register now for free, visit CardioCarelive.com (http://www.CardioCareLive.com).

About CardioCareLive

CardioCareLive, a medical conference that takes place entirely online, enables healthcare practitioners and others interested in understanding and managing cardiometabolic risk factors to learn, connect and interact through powerful Web-based software and services.

CardioCareLive is produced by PlatformQ (http://www.platformq.com), whose mission is to connect people, companies, organizations and associations worldwide to meet, interact and learn from leading experts and thought leaders through proven interactive tools at online events.

CardioCareLive and PlatformQ are trademarks of PlatformQ, LLC. All other trademarks or service marks are property of their respective owners.

About Metagenics

Metagenics, Inc. (http://www.metagenics.com) is a life sciences company and the premier manufacturer and distributor of science-based medical foods, nutraceuticals and therapeutic lifestyle change programs marketed to healthcare professionals. As a leader in the fields of nutrigenomics and functional medicine, healthcare practitioners around the world rely on Metagenics' products and services to help their patients achieve a lifetime of good health.

Press Contact: Sal Giliberto, 617-938-6006.

###

Contact Information Martha Collins

PlatformQ, LLC.

http://www.CardioCareLive.com

(617) 938-6008

Eye Care Profession Receives U.S. Occupational Listing

Eye Care Profession Receives U.S. Occupational Listing

The ophthalmic allied health profession received official notification of approval for a separate occupational classification, Ophthalmic Medical Technician, from the United States Bureau of Labor's 2010 Standard Occupational Classification (SOC) Committee.

St. Paul, MN (PRWEB) February 16, 2009 -- The Joint Commission on Allied Health Personnel in Ophthalmology® (JCAHPO®) http://www.jcahpo.org announces that the ophthalmic allied health profession received official notification of approval for a separate occupational classification, Ophthalmic Medical Technician, from the United States Bureau of Labor's 2010 Standard Occupational Classification (SOC) Committee. JCAHPO calls the new occupational classification a landmark decision.

"This is a historic milestone for the ophthalmic allied health profession," remarks JCAHPO President William F. Astle, MD, FRCS(C), Dipl. ABO. "Ophthalmic Medical Technicians are important in the eye care team as ophthalmology becomes more technologically oriented, and confronts the challenges of an aging patient population. This is a significant measure of how much this profession has evolved into its own, and an empowering validation of this occupation's professional merit," adds Astle.

The 2010 SOC system is used by federal statistical agencies to classify workers into occupational categories for the purpose of collecting, calculating, and disseminating data. For an occupation to be accepted for inclusion in the SOC, it requires a set of uniquely identifiable skills. The first set of skills is related to the complexity and range of tasks and duties, including knowledge and experience. These are defined by preparation levels and credentials, and considered necessary for new entrants to an occupation (skill level). The second set is related to both the type of work performed and the nature of the work activities.

Under the 2000 SOC listing, ophthalmic assisting was classified under Other Healthcare Support Occupations (Medical Assistants). Every ten years, the occupational listings undergo an extensive review. The Ophthalmic Medical Technician is one of many allied health professions impacted by this sweeping reclassification. Ophthalmic Medical Technicians are now classified under the major category of Health Technologists and Technicians, and the sub-group of Health Practitioner Support Technicians and Technologists. The former grouping excluded important tasks and responsibilities of Ophthalmic Medical Technicians that require more advanced, clinical, and overall medically detailed skills and knowledge than those of the general Medical Assistant.

Although the new occupational listing is identified as Ophthalmic Medical Technician, the SOC listing encompasses all three levels of JCAHPO certification, Certified Ophthalmic Assistant (COA®), Certified Ophthalmic Technician (COT®), and Certified Ophthalmic Medical Technologist (COMT®). The term "Ophthalmic Medical Technician" communicates the complexity and range of tasks from "assisting" that differentiates this profession from medical assisting.

JCAHPO leadership notes that the SOC decision will facilitate heightened public awareness and aid in recruiting more people into the profession. "The new classification will identify this profession as a definitive career pathway separate from other health personnel disciplines, and ultimately have a profound impact on the ongoing development of the Ophthalmic Medical Technician profession," says Astle.

For more information on JCAHPO or information on a career as a certified Ophthalmic Medical Technician, visit www.jcahpo.org or call (800) 284-3937.

JCAHPO is a non-profit organization that has been providing certification and training for eye care excellence since 1969. More than 17,000 ophthalmic assistants, technicians, and technologists in 22 countries are JCAHPO-certified.

###

Contact Information JCAHPO

JCAHPO

http://www.myeyecareer.org

(800) 284-3937